sinclair interim trade statement suggest good start year
solid perform ex-u good progress in-hous us sale forc
assess competitor risk btg crofab asset call
physician ground see risk btg approach revis estim
posit us meaning consensu move under-perform june
addit think approv pneumrx go prove difficult expect
base recent adcom panel
hansa medic present updat long-term risk-benefit profil
kidney transplant american transplant congress allograft surviv
probabl estim patient
one patient think updat de-risk clinic regulatori
pathway go forward kt
indivior report fda approv dr reddi suboxon film
gener think neg compani dr reddi pursu at-risk
launch indivior file temporari restrain order halt launch
activ evalu downsid risk due gener competit
think reduct guidanc unrealist albeit believ
bring forward realiti alreadi factor medium-term forecast focu remain
sublocad see asset
north american colleagu note number updat read-across
name medtron diabet divis growth platform
read-through convatec id franchis move toward minim invas surgeri
reson well siemen healthin biomup competit benchmark
moln mm competit gene therapi santhera car-t
fierc competitor r/r dlbcl
takeaway find document
takeaway month page
model updat forecast chang page
valuat tabl sector perform chart page
month ahead trade idea page
versu consensu upcom result page
newsflow north america page
eu investor need know page
price market close bst june unless otherwis note
takeaway month eu healthcar research
sinclair pharma interim trade statement first five month year show
strong momentum sinclair ex-u busi good progress us in-
hous sale forc ellan brazil key market aesthet
perform deep dive analysi competitor risk btg key pharma
asset crofab revenu estim group gross profit ahead
upcom competit conduct call physician
poison specialist assess potenti risk call see recurr cost
copperhead label key theme crofab competit crofab
profit asset divis disproportion impact ebit
ep think competit pronounc impact btg
keep declin zytiga asset varithena repneu yet take
whilst revenu ebit estim move margin
number includ cut top ebit line respect
put us meaning consensu june sotp valuat move
rate chang under-perform sector perform
addit btg report neg outcom adcom meet pneumrx
whilst anticip neg outcom base brief document releas
ahead meet think clear neg product
hansa medic present updat long-term risk-benefit profil
kidney transplant american transplant congress seven-year allograft
surviv probabl estim
patient one patient use ibox risk predict score integr
approach determin transplant surviv take
immunolog
epidemiolog think updat de-risk clinic regulatori pathway
go forward kidney transplant
histolog
indivior report fda approv dr reddi suboxon film
gener whilst unexpect given dr reddi receiv minor last quarter
think neg compani dr reddi purs at-risk launch
indivior file temporari restrain order halt launch activ
evalu downsid risk due gener competit think
product launch could lead reduct manag guidanc
whilst seem high believ bring forward realiti factor
medium term forecast focu remain sublocad see
elsewher morphosi announc partner roch start enrol
phase trial ganterumab patient earli alzheim diseas antibodi
test two phase trial patient primari complet date
estim juli whilst new news slightli earlier expect
move timelin forward
june
highlight eu healthcar research
much pain gain
perform deep dive analysi btg key asset crofab see
competit launch anavip unlist compani bioclon diseas
therapeut us distributor octob assess impact competit
crofab evalu import crofab btg clinic data
look like spoke physician ground
crofab lead asset btg pharmaceut divis gener
sale group revenu whilst product account
total group revenu think disproportion impact group ebit
ep due high drop product acquir
prother acquisit crofab price sinc whilst volum
remain broadli flat
pharma divis gross ebit margin
compani account capit market estim
revenu set declin product instanc zytiga varithena
repneu yet take see meaning gap profit approach
crofab sale declin sinc pharma divis mainli use cash cow
fund invest divis im strip crofab pharmaceut
gross margin assum support cost relat crofab btg remain
product busi actual unprofit
exhibit import crofab btg
split btg divis
strip crofab product
compani account capit market estim
therefor think market share loss crofab would detriment impact
btg invest case
assess product adopt look avail clinic data anavip
compar crofab spoken physician poison specialist
ground whilst anavip show superior trial use
copperhead snake bite label crofab appear use larger number
vial per treatment compar crofab symptom recurr rate lead
rehospitalis happen extent anavip compar
use crofab call learnt specialist treat rattlesnak bite see
lower recurr risk materi benefit specialist treat rattlesnak
bite copperhead learnt would put use anavip
patient time anavip may also get label extens impact price yet
determin need wait launch anavip octob
assess full
june valuat move downgrad rate
under-perform sector perform assign lower valu pharma im
divis slightli off-set lower cost base small uplift licens
higher zytiga revenu see valu im divis think
valu could enhanc acquisit convinc
off-set potenti declin crofab medium/long term
fulli make differ medium term
sotp valuationmethodologyrisk adjustmentmp/shun-risk un-risk p/sh downsid downsid p/sh old p/shchangenotecrofabdcfapprov bioclon asset gain greater tractiondigifabdcfapprov divis lower profitabilityvoraxazedcfapprov divis lower profitabilityvistogardrnpv approv back copharmaceuticalsdcf rnpv lower digifab profitabilityintervent oncologyrnpv current revenu run rate eu/usrepneu eudcfapprov valu given lack near term revenuerepneu usrnpv eu us approv expect reimburs dcfapprov given code dr willing utiliseintervent medicinedcf rnpv off-set move dcf yearzytigadcfapprov remain central
carv nich within med-tech space
btg ln much pain gain
valuabl
differenti struggl see alon justifi current share price
meaning risk approach crofab specif captur
within consensu believ investor look elsewher see
downsid risk like move under-perform sector perform
hmed anoth posit indic surviv estim
hansa medic present updat long-term risk-benefit profil
kidney transplant american transplant congress prior atc
present two-year followup data investigator-l phase trial
supervis professor stanley jordan show good patient graft surviv
without elev infect risk seriou advers event addit seven-year
allograft surviv probabl estim
patient one patient use ibox risk predict score integr
approach determin transplant surviv take
immunolog
epidemiolog new inform view updat surviv
estim de-risk clinic regulatori pathway go forward
histolog
btg fda adcom brief doc suggest tougher time pneumrx approv first
fda publish brief materi ahead thursday adcom btg pneumrx
elevair product releas think product could tougher time
gain condit approv origin expect data
known investor sinc public point rais fda appear show
concern safeti risk/benefit profil product even subset
patient btg focus data upon fda discuss option
condit approv base upon post market studi evalu safeti
efficaci target patient sever emphysema hyperinfl lung despit
extens post-approv studi plan outlin btg initi view fda
could well ask target data first
sph positive/reassur trade statement first five month year
sinclair pharma issu trade statement compani period
end-may highlight us strong momentum sinclair ex-u busi
busi track deliv mid-teen growth constant currenc ii good
progress us in-hous sale forc sale first two month
ahead budget reiter guidanc us sale least constant
currenc iii good progress ellan brazil initi demand
exceed budget albeit detail given group revenu growth expect
second half weight line previou year match prior guidanc whilst
may want see progress updat health
balanc sheet think ev sale grow
key asset re-launch us risk worth potenti reward
morphosi announc partner roch enrol first patient new phase
trial gantenerumab gant patient earli prodrom mild
alzheim diseas gant test two trial
patient primari endpoint complet date estim juli
expect enrol start earli new news posit
slightli month move timelin forward particip need
evid beta-amyloid patholog prior enrol primari endpoint
trial assess sign symptom dementia use clinic dementia
rating-sum box cdr-sob score standard endpoint alzheim trial
indv dr reddi approv unexpect sentiment test
dr reddi receiv fda approv gener version suboxon film
indivior key product us account major revenu present
news clearli neg indivior albeit unexpect given
recent minor dr reddi last quarter suggest approv
immin would highlight dr reddi launch risk
rule current appeal process rule three addit orang book
list patent would neg indivior current forecast
assumpt spite updat remain posit medium long term
potenti indivior investor see materi neg movement
opportun given legal complex suboxon film launch ii
valu sublocad see asset
btg neg outcom adcom panel
fda adcom panel vote use pneumrx coil adcom panel
whilst fda alway follow adcom panel decis customari
henc think approv unlik whilst anticip neg
outcom adcom panel fact vote clear cut
expect clearli neg product see impact share
price today pneumrx coil make sotp valuat whilst
end product develop could help product gain approv later
date think consensu revenu may risk
last week held kol call investor discuss competit impact anavip
crofab build upon prior discuss kol net result still
convinc btg competit problem anavip price remain key
unknown potenti also label copperhead even bar see share
loss like ahead consensu expect
indv ln evalu downsid earli gener competit
gener film launch could see manag guidanc come
ultim think bring forward realiti alreadi assum
medium-term estim focu remain sublocad whilst share may
struggl find form certainti product clearer think reaction
provid attract entri price downsid arguabl price
model updat forecast chang
made small forecast chang ahead convatec interim result august
reflect result primarili ostomi cc infus devic also
recent market peer commentari price pressur woundcar make
chang margin assumpt would note expect materi
weight gross margin impact ebit margin
exhibit summari forecast chang
exhibit summari underli growth rate chang
year decemb new chang new chang advanc wound bpsostomi bpsinfus bpstotal organ revenu bpsyear decemb new chang new chang advanc wound bpsostomi bpsinfus bpstotal cer revenu bpsyear decemb new chang new chang advanc wound bpsostomi bpsinfus bpstotal revenu bp exhibit group financi estim
incom statement year decemb wound currenc growth rate currenc growth rate currenc growth rate devic currenc growth rate currenc rate margin margin margin acquir underli amortis held profit incom report fd normalis continu fd number group share fd exhibit group financi estim
metric year decemb debt ebitda debt per share yield work per share exhibit group financi estim
year decemb cash non-cash work cash associ flow cash discontinu share net sheet year decemb plant non current current long term current deficit newsflow calendar result march may result august novemb
healthcar valuat tabl sector perform chart
denot act broker note siemen healthin list march henc ep avail
price market close bst june
capit market estim factset price inform
companyrecimpli upsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate pharmaoutperform spec spec medic aboutperform spec seknanananananananananananahorizon discoverysector perform spec biopharma outperform spec partnersoutperform spec spec therapeuticsoutperform spec healthineerssector exclud morphosi salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan june
jan june
jan june
jan june
jan june
jan june
share exhibit coverag perform versu peer wider sector
jan june
jan june
jan june
hansa medicaldechra pharmaceuticalsabcami pharmaindivioreco anim groupcv groupudg care publicgenusclinigen groupcaretech holdingsmorphosysfts share price indexsmith nephewastrazenecaglaxosmithklinestoxx europ price indexshiremolecular partnershorizon discoveri grouphikma pharmaceuticalscambian groupspir care gp btgvectura groupbenchmark holdingssinclair pharmacircassia medicalnmc dechra pharmaceuticalsi pharmaindiviorabcammorphosysgenuseco anim groupcaretech holdingsudg care publiccv groupclinigen grouphorizon discoveri groupfts share price indexsmith nephewastrazenecaglaxosmithklinecambian groupstoxx europ price indexshirespir care gp btgbenchmark holdingsmolecular partnershikma pharmaceuticalssinclair pharmavectura pharmacircassia care publicindivioreco anim groupabcammolecular partnerscv groupclinigen groupsinclair pharmacaretech holdingsfts share price indexstoxx europ price indexhikma pharmaceuticalsshield therapeuticsmereo biopharma groupnmc convatec groupsantheraspir care gp hansa medicalcambian pharmadechra pharmaceuticalscircassia pharm btgvernalissmith nephewgenusastrazenecavectura groupianc pharmamorphosysglaxosmithklinebenchmark hold month ahead trade idea
look juli hansa medic interim result siemen
healthin earn well potenti readout trial kidney
transplant hansa medic pdufa date indivior depot
treatment schizophrenia
juli hansa medic interim result main financi metric
stage focu cash posit given compani still develop
focus forecast net cash posit sek equat around
follow secondari rais decemb see hansa medic
fulli fund take approv process kidney transplant
lead indic note
key focu upcom readout investigator-l phase trial
highd studi expect releas earliest could
juli
last week two updat investigator-l trial
show encourag long-term follow-up data treat patient sparc
estim seven-year allograft surviv probabl sparc would
point long-term surviv estim year put least
line desensitis techniqu consid sensit level
patient treat seriou advers event far report
think seen posit regul
siemen healthin earn juli look updat atellica
solut roll-out diagnost segment well organ sale develop
ii organ sale growth adjust profit margin imag advanc therapi
diagnost watch placement rate atellica solut platform
particular ratio convers system instal base versu
competit win turnaround diagnost main upsid opportun
view siemen healthin expect come scrutini everi quarter
question placement rate custom win
recal earn sparc siemen healthin deliv
strong perform imag segment diagnost manag off-set weak
whilst advanc therapi segment clearli disappoint weaker margin
organ growth expect us consensu
last two week share price trade reach peak
june sinc
see indivior one watch week ahead number newsflow
item keep eye
detail earlier indivior report fda approv dr reddi
suboxon film gener subsequ file temporari restrain order
court date june outcom expect within week
formul risperidon
use
later month juli pdufda date pipelin asset
schizophrenia treatment model estim launch
rnpv analysi yield account price target indivior
submit nda octob sparc basi pivot phase
trial demonstr statist clinic improv
compar placebo base chang mean posit neg syndrom scale
panss total clinic global impression-sever ill cgi- score week
see approv like think indivior make decis commerci
futur asset mean might potenti sell dug focus mental
anticip clinigen trade statement juli exact date
confirm look gross profit growth perform divis ii net
debt figur iii updat quantum pharma integr estim
line consensu revenu gross profit ebitda ep
follow end februari saw lumpi perform
clinic trial servic divis note trigger neg share price
reaction thereaft sparc saw share price declin reach
june think reflect underli qualiti clinigen busi
recent announc clinigen partnership bristol-my
squibb global pharma compani leader oncolog space
distribut bm product south africa sparc think speak
clinigen expertis qualiti addit us sign right tri act
see posit clinigen leader provis access
unapprov drug note
would see updat clinigen report financi line consensu
like lead materi re-rat would buyer ahead result
gp divis
dechra trade statement look growth rate per divis
group ii updat integr recent acquir dutch-bas ast
farma le vet beheer busi iii cash gener
estim line consensu top line ahead
ebitda ep acquisit ast farma le vet beheer note
interim result note dechra share price gone reach
peak june
given re-rat ahead result would cautiou buy ahead
updat whilst see long-term potenti dechra share re-rat pe
abcam trade statement look report cer growth rate
abcam end market ii updat move relat end market instanc
immunoassay abcam insid program
estim line consensu top line ahead
ebitda ep last three week abcam share price strong run
peak june
interim result march note manag rais cer revenu
growth guidanc whilst profit figur slightli
lower forecast think pure phase relat consid
estim achiev
abcam deliv in-lin set result see consensu upgrad like
abcam like hold premium rate
follow interim trade statement detail earlier note
anticip increment updat revenu growth rate per product ii net
sinclair recent move use in-hous sale forc silhouett us
reiter guidanc us sale least cer would keen
hear initi feedback like potenti plan increas
size salesforc time
share still recov tough end start follow
disappoint almiral share near all-tim low ev sale
firm buyer level
revenu divis
revenu divis
revenu product
potenti catalyst timet coverag coverag peer
exhibit potenti catalyst timet coverag coverag peer
note indic project result releas date
stockjulyaugustseptemberabcam abbott laboratori result juli result juli abcam trade updat tbc qiagen result juli result aug biorad result aug result tbc horizon discoveri result tbc acacia pharmateva result aug result aug heron result aug result juli result aug integra lifesci result aug biom result tbc result aug result juli result juli varian medic system result juli merit medic system result juli result aug icu medic result aug result juli astrazeneca result juli result trade updat tbc cumberland result aug result tbc convatec smith nephew result juli result aug result aug coloplast result aug result aug ambu result aug medic solut result sep trade updat tbc eli lilli result juli vetoquinol result juli result aug phibro result aug result tbc hansa medicalhorizon discoveri abbott laboratori result juli result juli abcam trade updat tbc qiagen result juli result aug biorad result aug discoveri result tbc abcam result tbc indivior result juli camuru result juli indv result tbc pdufda date use schizophrenia juli result aug result aug partnersgilead result juli allergan result juli molecular partner result aug result juli roch result juli morphosi result aug result aug sarepta result aug result sep siemen healthineersabbott laboratori result juli result juli ge result juli labcorp result juli philip result juli varian medic system result juli roch result juli quest diagnost result juli healthin result juli qiagen result juli result aug result aug elekta result aug pharmainterim trade updat tbc allergan result juli pharma result tbc vectura novarti result juli astrazeneca result juli interim trade updat tbc hikma result aug result tbc out-licens deal nda submiss result tbc potenti feedback fda meet track statu hansa result juli argen-x result aug readout month follow-up data tbc
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
factset capit market estim
stockmetricconsensu fcst fcst fcst profit pharmasiemen healthineersabcamindiviordechraconvatecclinigen newsflow item north america
north american colleagu believ key newsflow revolv around
diabet growth driver abbott read
convatec move toward minim invas surgeri
diabet growth
platform medtron
posit readacross
bullish
reson well siemen
healthin biomup
glenn novarro brandon henri attend american diabet associ ada
confer manag session investor analyst team
confid diabet major growth platform abbott
sophist glucos monitor system back real-world data
receiv regulatori approv includ children age well ce mark
look launch minim insulin pump system select eu countri later
year view posit convatec id franchis manufactur insulin
pump tube
lack surgic skill capabl
glenn brandon provid key takeaway investor day
nyc estim core surgic procedur perform world-wide
done mi split procedur laparoscop
approach procedur robot approach barrier mi adopt
lack awar mi
clinical/econom benefit insuffici oper room infrastructur
core surgic procedur done open manag believ
procedur done mi move toward mi reson well
siemen healthin advanc therapi segment provid equip
imaging-guid therapi biomup look commercialis mis-
note celgene/bluebird report addit phase data car-t
therapi program multipl myeloma mm whilst data impress
respect proport patient respond therapi total
patient see durat respons import benchmark
molecular partner mm median progress free surviv
higher-cel dose cohort mo low dose far phase
studi seen low dose cohort patient
respond patient still on-going time data cut durat
respons month month given complet data cohort
present end possibl could see longer durat
plu would initi data higher dose-cohort overal see moln
period addit result lead oncolog asset key could
help clarifi multi-darpin draw attent stori
continu like long-term promis multi-darpin
initi posit proof-of-principl data sarepta gene therapi program
dmd neg santhera idebenom program whilst
idebenom patient popul advanc stage henc
directli compet patient popul see like
approv gene therapi impact idebenom potenti elig patient
popul order estim better level impact wait
long term data gene therapi durabl effect
brian team host multi-physician dinner kol specialis
cellular therapi discuss latest data car-t therapi yescarta kymriah
dlbcl link report discuss see sever point
make us feel competit car-t therapi morphosi would fierc
henc market share r/r dlbcl seem reason first clear
sinc car-t therapi launch centr manag adapt car-t
operational/ logist process also manag side effect better
prefer car-t therapi aggress higher efficaci yescarta
oppos milder kymriah interestingli car-t therapi evolv fast
accord kol potenti re-dos car-t also
combin checkpoint inhibitor btk ibruitinib henc potenti
improv efficaci lastli interest academ centr manufactur
car-t could untim reduc cost time treatment
phase data multipl
moln
posit data sarepta
gene therapi program
santhera idebenom
car-t
remain high
exhibit stock cover dougla miehm
titl link note
nvln announc myalepta receiv
posit chmp opinion morn novelion announc receiv posit opinion recommend ema author
chmp myalepta patient gener partial lipodystrophi ld chmp rule review european
commiss ec approv indic expect mid-year specif chmp recommend grant market
author myalepta adjunct diet replac therapi treat complic leptin defici ld patient
confirm congenit gener ld acquir gener ld adult children year older confirm
famili partial ld acquir partial ld adult children year older standard treatment fail achiev
morn oncolyt disclos price detail public offer initi announc yesterday close
view issuanc overli surpris given recent clinic corpor develop compani overal view onc
remain unchang continu view favour set-up
dr announc sale imd term
medic facil announc sale imd morn dr announc complet sale integr medic deliveri
harri comput corpor imd own dr gener revenu provid third-parti busi
solut healthcar entiti exampl revenu cycl manag term transact disclos releas
vrx receiv duobrii larg
attribut pharmacokinet data
duobrii receiv morn valeant announc topic psoriasi agent duobrii receiv complet respons letter
fda releas indic specifi defici relat clinic efficaci safeti
chemic manufactur control process respons note question regard pharmacokinet pk data
valuat updat plu thought
mid-year consensu like low
updat valuat provid thought remaind year balanc view remain larg unchang
see neg catalyst next six month guidanc increas like howev valuat keep us sidelin
clariti may disappoint
busi updat summari earlier afternoon promet host busi updat call design highlight compani
progress sinc overal manag reiter continu moder cash burn gain addit interest
big pharma pertain potenti licens deal ryplazim believ commentari provid call
vagu best perhap need given track record set overli optimist deadlin
exhibit stock cover randal stanicki
titl link note
confid outlook highest
host dinner chairman/ceo bruce cozadd dinner discuss broad leav feel better tail
option confid target busi develop view deal like comfort recent
 momentum continu overal still see materi dcf valuat disloc stock think ultim close
focus week
neulasta action date apss
focu past week sector squar like continu week compani
provid result await strateg review link stock reaction mute heard signific push-back
recur question base incom call whether sharehold push chang becom formal/voc
like remain focu week see primer/strateg report background link host dinner thur
chairman/ceo bruce cozadd link come ahead webcast apss tue et final debat high around
whether partner biocon get approv neulasta biosimilar expect color mon
close announc receiv fda approv fulphila pegfilgrastim-jmdb first approv biosimilar
neulasta fulphila second approv biosimilar develop collabor biocon follow last
year approv ogivri biosimilar herceptin announc coincid today target action date expect
follow commerci launch come week bottom line believ import develop help
set tone import pipelin updat advair restasi ii lend support number requir pipelin
convers hit
expect fulphila approv pend biosimilar approv creat signific headwind neulasta sale
receiv fda approv
neulasta biosimilar posit signal
pipelin thought
fulphila approv fda pt
 formal letter sharehold
call chang thought post
discuss investor behind
appaloosa senat invest group made public letter agn board director date today well two previou
letter date may april letter outlin two invest firm strong suggest chang follow may
strateg review result detail note strateg review outcom first step three bucket view
follow releas letter short time ago spoken one invest firm involv
neulasta biosimilar approv focu
gx advair thought set-up
share approv pegfilgrastim/neulasta biosimilar versu expect bring pipelin
halo focu shift next three near-term opportun gener advair action date provid thought
bottom line see bia upward approv momentum remain concern greater need base busi
support limit upsid
meet aaps/sleep
manag dinner remain buyer
present sever abstract apss/sleep confer host present phase long-term safety/efficaci
studi tone solriamfetol pediatr data xyrem hear anyth new post thur dinner data remain
compel remain import part stori reiter op rate
theme watch eu investor meet
global channel check focu
attend joint confer intern gener biosimilar medicin associ igba medicin
europ next week budapest present particip panel well separ meet investor across
europ confer attend global gener manufactur consist sever panel present two day
along network event gener industri global natur year confer come us pressur make
ou eu particular bigger import part revenu base global gener compani coverag
one five major theme detail gener primer gener primer structural/cycl path forward
watch call turn bull/bear debat compani
titl link note
 result atogep phase
trial encourag thought
morn report posit top-lin result phase trial atogep episod migrain prevent activ
treatment arm met primari efficaci endpoint chang baselin mean monthli migraine/prob migrain headach
day across treatment period safeti key question mark oral cgrp importantli
signal hepatotox intend continu phase program follow discuss regulatori author
gx advair shift focu base
busi weak guidanc risk
view
fda identifi minor defici gener advair relay debat expect two
issu have/do think base busi pressur wors let pipelin increasingli need backfil ii
street meaning over-model gx advair stock like pull back tomorrow/through guidanc risk real better entri
point rebas number
igba/medicin europ gener
confer confer takeaway
agn/jazz
attend joint intern gener biosimilar medicin associ igba medicin europ confer
present view gener outlook met industri particip channel contact igba global associ
coordin country/region member includ aam us whose senior leader particip along eu execut
myl/teva other meet becom import given increas ou gener exposur relianc ii
common gener sector theme executives/contact year confer held budapest believ buy/sell-
side coincid european investor meet
three main theme lot takeaway
meet chairman/ceo
host lunch/meet chairman/ceo brent saunder occur interest time focu high given debat
around strateg outlook pipelin potenti view leav meet activist focu keep floor stock
improv sentiment come continu earn momentum addit favor pipelin updat debat
latter also option
settlement teva add visibl
import product
morn announc enter settlement agreement teva actavi subsidiari resolv rytari
patent litig term agreement grant teva licens sell gener rytari juli earlier
certain circumst view import posit updat reduc risk key product
ii provid clariti around potenti life cycl manag strategi use
 posit competitor data weigh
stock fundament chang
morn announc top-lin result two phase studi evalu total knee arthroplasti tka
ii breast augment long-act extended-releas formul bupivacain meloxicam expect
compet exparel market post-op pain manag bottom line surpris magnitud
move share clearli real competitor would emphas noth chang
fundament view continu see room two competitor market see even exagger valuat
dispar believ reflect low expect
cost call option evolv
offer uniqu exposur larg evolv women market lack innov non-hormon on-
demand contracept lead product amphora fill void expect debat around commerci potenti survey
women support peak assumpt current valuat reflect littl call option meaning market initi
host meet manag focu upcom expect dsuvia adcom meet ahead
pdufa date stori set shift commerci today announc eu approv dzuveo anticip us nda
resubmiss zalviso add addit opportun focu stock set pick move catalyst-heavi
exhibit stock cover glenn novarro brandon henri
titl link note
question
elekta report adjust ebita consensu constant currenc revenu order growth larg
line elekta main competitor report net sale sek fce sek flat y/i constant currenc fce
adjust ebita sek came consensu sek gross order book sek fce sek
y/i constant currenc fce elekta instal base y/i vs elekta agreement place
mr-linac system order ce mark still expect end june manag
expect y/i constant currenc net sale growth fce ebita margin fce manag restat financi
guidanc compar consensu appl appl
report present key question ask manag team upcom analyst day confer
med-tech takeaway
earn scorecard strong quarterli result investor sentiment remain strong takeaway earn season
includ major end-market stabl us spine market remain challeng capit deploy strategi still intact
endoscopi medsurg revenu import busi sever reason address larg market opportun
grow high single-digit aid shift open surgeri non/less invas endoscop procedur medsurg
margin higher corpor averag fragment natur variou end market offer attract opportun
expect isrg/trxc
believ move open mi growth driver mitg busi host investor day nyc
manag estim core surgic procedur perform world-wide done minim invas mi consist
procedur lap approach procedur robot approach barrier mi adopt includ
lack surgic skill capabl lack awar mi clinical/econom benefit insuffici oper room
infrastructur core surgic procedur done open manag believ procedur
done mi estim increment market opportun shift patient open mi everi
weak share wit yesterday trade transient upward momentum resurfac market digest
wealth inform share biennial investor day manag express high degre confid revis
long-rang financi target believ achiev leav room upsid reiter outperform price target
thought potenti syk/bsx
overal would view potenti acquisit unfavor strateg rational deal
believ bar valu creation high especi given compani valuat potenti integr risk
warrant premium valuat compar peer owe superior clinic data technolog rais price target
note highlight sever posit develop support outperform rate
believ fda approv augment inject re-acceler augment sale repres upsid current
discuss acquir
recov recent loss post announc discuss acquir
sirtex medic board director say
cdh-cgp bid superior
sirtex decid support cdh-cgp propos believ made right decis rais offer
titl link note
med-tech impact china tariff
chines tariff impact medic suppli devic space reduc offic unit state trade repres
ustr today releas list product import china subject addit tariff recal april ustr
announc propos list product could subject addit duti sought comment interest
person appropri trade advisori committe list contain variou medic suppli devic categori well
hospit capit equip ustr section committe conven three-day public hear may may
presid trump issu statement announc june ustr would releas final list good
import china would subject addit tariff final list product issu today
cover separ tariff line valu trade valu good news medic suppli devic
manufactur impact tariff reduc final list rel propos list
sever medic suppli devic categori remov updat list product import china
impact new tariff morn offic unit state trade repres ustr releas updat list
product import china subject addit tariff updat list product cover separ tariff
line valu trade valu list contain variou medic suppli devic categori well hospit
capit equip categori like defibril orthoped implant needles/catheters/syring dental hear aid
includ previou section tariff list either larg complet remov updat section tariff list
howev categori like pacemak radiat therapi ct mri x-ray remain updat section tariff list
trade tension china continu escal presid trump announc direct trade
repres ustr identifi chines import good potenti addit tariff rate addit
presid trump threaten place addit tariff chines good import
ministri financ china choos retali potenti futur tariff recal come ustr
announc potenti tariff good import china go effect juli ministri
financ china respond similar tariff potenti tariff good import
analyst meet ada tariff thought
med-tech remain one in-favor sector within healthcar investor analyst meet ada
highlight ada analyst
came away ada confid diabet major growth platform rate outperform
exhibit stock cover frank morgan
titl link note
news nashvil weekli
perspect healthcar industri
sector price perform week end june healthcar servic stock under-perform broader market
health servic select index spsihp declin versu gain skill
nurs strongest perform sub-sector last week acut hospit downtick vs declin
prior week manag declin vs uptick prior week specialti weakest perform sub-sector
last week
virginia medicaid expect bring dual
benefit lpnt
use capit impact
news nashvil weekli
perspect healthcar industri
estim net ep benefit nearli expand coverag rate enhanc virginia
take-away view acquisit half kkr stake compani favor given immedi expect accret
approxim base ep estim believ share purchas like better lower-risk use
cash near term given high valuat market importantli deal impact strategi
signific revolv expans current work expect deal announc end summer
sector price perform week end june healthcar servic stock perform line broader market
 health servic select index spsihp gain senior live
strongest perform sub-sector last week acut hospit gain vs downtick prior week manag
gain vs declin prior week ambulatori surgeri weakest perform sub-sector last week
downgrad sector perform kkr
deal place
lower rate evhc sector perform outperform stock within deal price reduc
price target
partnership humacyt posit fm potenti commerci new technolog vascular access lower total cost
healthcar rule t/time warner
case bode well mco/pbm vertic
tuesday close district court rule without condit justic depart favor
 t/time warner merger everi case theori judg specif uniqu merit conceptu outcom
bode well larg vertic integr transact healthcar segment particularli aetna pend acquisit
pend acquisit express script
enrol tracker add
june show
releas medicar advantag part enrol data june ad net member
roll sinc may bring total enrol membership country-wid increas sinc june last year
reflect increas penetr medicar advantag membership among medicar elig popul year-to-d
membership grown reflect larg bolu new member join roll open enrol period
medicar part enrol declin sequenti increas sinc june last year
news nashvil weekli
perspect healthcar industri
sector price perform week end june healthcar servic stock outperform broader market
health servic select index spsihp gain versu flat perform skill
nurs strongest perform sub-sector last week acut hospit gain vs gain prior
week manag gain vs gain prior week hospic weakest perform sub-sector last week
titl link note
progress behavior legisl
improv access care
take-away passag hous bill illustr increas momentum congress ultim repeal imd
exclus entir would repres signific expans address market behavior provid
given fact companion bill senat believ bill good chanc becom law
news nashvil weekli
perspect healthcar industri
sector price perform week end june healthcar servic stock outperform broader market
health servic select index spsihp gain versu declin
ambulatori surgeri strongest perform sub-sector last week acut hospit declin vs gain
prior week manag gain vs gain prior week temporari staf weakest perform sub-
sector last week
turnaround effort continu
take-away encourag continu effort leas portfolio restructur agreement
improv cash flow elimin low-noi properti high rent capital-expenditure oblig simplifi compani
contractu arrang associ ridea jv addit similar recent leas agreement venta
agreement free compani change-of-control hurdl
 despit larg headlin figur juri
alter rule
take-away believ reason expect damag nyse sp wrong death lawsuit
reduc significantli elimin appeal process could take time present possibl overhang stock
separ believ today drop-dead date place statewid measur california fall ballot go without settlement
seiu initi cap revenu dialysi compani cost novemb ballot
exhibit stock cover brian abraham
titl link note
celg announc hire new cfo david elkin current cfo peter shift strateg role ahead plan
retir see valu addit perspect incom cfo new member
manag board bring critic time compani continu believ stock fundament inexpens
chmp expand translarna label
oral jak inhibitor xeljanz approv week fda recommend posit today chmp ulcer coliti
base feedback ibd physician recent day see note believ label expans highli
anticip physician look deploy new oral option uc crohn believ uptak plan monitor
close could import litmu test ultim opportun oral jak modul better profil co
like gild/glpg filgotinib celg ozanimod univers repres import valu driver continu view
substanti room new oral therapi ibd space multi- potenti asset even account competit
impact price market share
morn chmp issu posit opinion expans translarna label eu includ dmd patient nonsens
mutat age year old believ label expans younger pediatr patient would
increas number eu patient elig treatment translarna could increas peak eu translarna sale
launch translarna pediatr popul expect begin shortli given initi diagnos
genotyp younger patient eu infrastructur place rapidli identifi initi translarna treatment new
patient segment help compani reach guidanc y/i sale compound-annual-growth-rate believ potenti label
expans mostli expect estimate po
first pass label olumi approv fda appear reflect unfavor scenario drug
futur opportun though level believ limit valu share royalti drug
new ph ii myeloma data includ new follow-up previously-report dose-escal pt earli respons data
dose-expans pt continu show promis overal profil though respons rate appear bit lower perhap
yet matur discuss around long-term relaps overal activ refractori popul along
safeti profil continu look accept especi cellular therapi solidifi potenti
import role futur mm paradigm continu estimate prob-adj out-yr sale oppti could see celg share
start move higher pipelin agent like becom increasingli appreci
saturday even host multi-physician dinner includ kol clinician/research major academ
center special cellular therapi detail discuss cover impress bcma car-t data view present
futur scientif commerci dynam among car-t modal prospect therapi allo car-t solid tumor
cellular therapi potenti ruxo gvhd overal felt posit mix celg posit less
enthusiast
new transcend result show competit profil dlbcl though compar across studi vs yescarta kymriah
complic convinc physician agent properti advantag enough warrant broad switch practic
pattern away establish competitor car-t approv could still uphil battl still celg receiv
littl credit car-t program pipelin matter result look good enough help improv overal tone
around stock
attend confer chicago -- summar notabl takeaway relev cover
compani celg
titl link note
appoint dr rodino-klapac
reiter focu gene therapi
new paper show promis
cellular therapi solid tumor
see multipl posit read-through aldr news friday aimovig launch strong gate per
im rx number highlight potenti larg cgrp opportun chmp posit recommend aimovig show
intern align posit benefit/risk class though share strong late march
low aldr remain favorit small-cap given still-underappreci eptinezumab opportun view expect
addit upsid share
tidbit celg analyst/investor event found interest reassur add detail
transcend data includ fact count full/cor denomin similar respons
bridg chemo major effect provid reassur competit efficaci cleaner safeti repres
somewhat apples-to-appl comparison car-t car-t tout cll interestingli celg particularli
excit cll highlight data prior confer open transcend cll studi
indic add data expect relev increasingli relev compani seem enthusiast impact
relev revlimid fl data present despit fail superior endpoint potenti revlimid
chemo-spar compar outcom highlight import conveni benefit physician speaker still
transform potenti cure earlier line celg investig defend relaps observ highlight
extrem refractori popul observ note unpreced agre truli transform
potenti move line could effect enabl function cure
morn announc appoint louis rodino-klapac ph vice-president gene therapi busi unit
head develop gene therapi gene edit program dr rodino-klapac lead expert gene therapi prior
appoint pi nationwid children hospital/srpt clinic trial microdystrophin gene therapi
treatment duchenn muscular dystrophi dmd co-inventor gene therapi construct use trial also
co-found cso myonexu therapeut compani recent establish partnership develop gene
therapi treatment limb-girdl muscular dystrophi
new articl publish natur medicin show promis initi result tumor-infiltr lymphocyt til -base cellular
therapi develop nci licens technolog util patient t-cell alreadi
infiltr tumor expand ex-vivo re-infus newli expand cell back patient target tumor
publish paper one patient er metastat breast cancer refractori multipl line prior therapi underw
treatment til patient tumor burden reduc week initi treatment
patient tumor radiograph resolv month post-treat
attend ph ii melanoma data poster went view updat data favor requir
buy-in concept invers dose relationship dose show meaning higher respons
higher dose someth acknowledg may discomfort biolog fulli understood
follow analysi ph ii poster discuss compani believ multipl line evid point
potenti real effect artifact increas confid -- given respons rate arm
believ clearli surpass would expect pembro alon -- good likelihood ph iii success dose see
littl credit share would buyer weak
share today believ part due paper natur medicin describ one patient breast cancer resolv
follow receipt tumor-infiltr lymphocyt til base cellular therapi develop nci though may
also follow-through posit yescarta tone physician present well recognit share
titl link note
updat investor meet
compani analyst/investor meet manag expand mani favor point ph ii
melanoma result previous detail discuss biolog rational activ outlin go-forward plan
asset acknowledg could remain difficult contextu contribut activ given variabl among
melanoma trial respons rate coupl ad wrinkl invers dose depend balanc given data biolog
mechan result intratumor approach continu see reason probabl ad benefit
success ph iii share reflect littl downsid limit heplisav-b valu continu see
attract invest io space
share consecut trade day anoth today vs ibb receiv mani
question potenti explan today downsid explor number possibl reason end find
signific fundament chang lead us believ may relat technical/fund flow
eisai report result ph ii trial bace inhibitor elenbecestat aka partner show stat sig pet
beta-amyloid reduct high dose concurr trend toward lesser cognit declin vs placebo though detail
pr critic understand meaning applic result overal view increment
support beta-amyloid hypothesi though significantli chang risk profil aducanumab
reson kol
posit glpg readout buy
weak
new ceo hire sensibl alder
imdz host analyst/investor breakfast featur three top kol immuno-oncolog dr carl june jean-yv blay
christoph flower physician detail imdz technolog context evolv io landscap overal thought
enthusiast mechanist rational imdz next-gen therapi well data
date walk away even confid belief likelihood success potenti market opportun imdz
clinical-stag next-gen program greatli underappreci compani valuat despit time taken
platform matur patienc like reward
chanc catch mru management team present new data meet clinic
program remain track compani enthusiast recent enter clinic mru
period execut key add result lead program roll could help clarifi
bispecif profil draw attent stori continu like long-term promis bispecif
platform product emerg expect share trade in-lin
downgrad pti sector perform outperform base mix data report today cf corrector
sign activ ph ii given lack clear benefit believ work need done fulli de-
risk asset yet enough confid profil construct share ultim
succeed pti remain rel uniqu multipl clinical-stag cftr modul success could creat
substanti valuat upsid asset de-risk move sidelin lower target
decreas po
believ tonight pti data highlight challeng show clear lung function benefit cf studi reaffirm view
weak readout glpg similar ph ii cf studi unfound present buy opportun share
morn aldr announc hire new ceo bob azelbi seattle-bas ex-juno commercial/oper industri
veteran repres sensibl low-risk choic guid aldr next stage develop offer addit thought hire
continu view aldr share under-valued
titl link note
interact bcrx-idra merger tool
continu upsid cgrp opportun
firefish data pot biib/nv
fda endors best-cas path
just-publish nejm articl use bezafibr gener drug avail europ pbc reveal symptomat
improv decreas pruritu along known efficaci previous present easl continu view beza usag
eu commerci risk ocaliva see major impact given current lack avail think
similar agent pbc remain worth watch longer term especi given view express accompani
editori nonetheless get out-year sale ocaliva assum penetr allow competit --
still believ enabl solid floor valuat see attract reward/risk ph iii nash readout
stockhold vote propos merger idra expect vocal support merger
bod largest sharehold compani two larg investor file document say plan vote
merger ahead vote construct interact tool help assess merit vs dilut sharehold
variou out-year revenu po estimate scenario describ detail base case merger look net neutral
us half valu combin compani approxim equal current price target remain higher
current share price keep us outperform rate
morn report episod migrain data oral cgrp antagonist atogep expect believ
competit overhang aldr share late though efficaci certain dose look similar inject question
dose long-term safeti remain overal data reaffirm belief oral cgrp antagonist place
futur migrain prophylact paradigm seem like displac inject significantli impair underappreci
market opportun aldr eptinezuamab yet anoth overhang see continu upsid opportun aldr
expect multipl updat week june curesma firefish studi ptct/roch oral splice modul
nvs/avx gene therapi program preview addit gene tx remain track enter clinic
expect updat come month increas focu particularli light recent valuat
deriv neuro gene tx program axon grow import pipelin diversif potenti sma
announc fda endors pivot path add detail expect compani call et
pr registr plan appear absolut best case around term would make rapid
least arduou lowest cost lowest-risk registr path expect strength today higher likelihood reach
market perhap sooner expect potenti multi-billion dollar game-chang depress therapi would
buyer share
endpoint dermatomyos
morn idra announc weekli inject tlr antagonist week meet
primari endpoint signific reduct cdasi score compar placebo
remov potenti player
view ph ii nash data present today galm glmd cover remov anoth potenti competitor futur
nash market posit
titl link note
today hh secretari azar appear educ labor pension committe washington take
question presid trump american patient first blueprint lower prescript drug price expect new
polici strict timelin implement propos blueprint announc today main theme emerg
senat frustrat drug compani lower price yet blueprint seem contain question
answer propos administr offer clear timelin propos chang start
benefit american patient blueprint includ provis work author previous draft legisl
address issu requir drug price tv commerci express willingness/desir administr work
congress pass legisl achiev drug price goal main take-away addit confirm propos
chang take consider time manifest eventu though believ fundament shift
toler citizen policymak continu drug price escal overal near-term concern major government
intervent wane continu expect upsid oversold larg cap biotech earn
morn announc collabor brammer intend provid manufactur capac clinic
commerci product microdystrophin gene therapi program gene therapi program recent obtain
myonexu deal investor present morn ceo doug ingram note partnership would help match srpt
manufactur capabl ambiti timelin get gene therapi market
gild/icpt quick thought report
mean nash player like
note unsubstanti report today bloomberg earli stage explor potenti sale recal
recent report posit ph ii data nash show placebo-adjust patient achiev nash resolut trend
fibrosi improv note recap reaction
follow addit detail favor path forward mdd outlin call yesterday updat
model reflect earlier mdd approv timelin align ppd/mdd launch/pricing/po estim out-year
revenu potenti increasingli like reflect share low-risk nt catalyst brex adcomm/approv ph ii data
see continu appreci potenti despit week upsid
gsk/viiv announc posit result morn gemini ph iii studi test dolutegravir-bas combo
treatment-na hiv pt show non-inferior efficaci tripl dolu truvada regimen though see treatment-
emerg resist studi key question regimen believ concern resist risk
real-world set make tripl cocktail drug choic continu see long-term share gain
help drive growth hiv franchis remain buyer expect bounceback
morn announc strateg partnership shionogi commerci japan taiwan south
korea chanc speak compani manag transact share today see
deal impact potenti acquir futur numer compani kite juno asian partnership
prior acquisit half up-front econom necessarili peg valu asset would use
weak buy opportun given bullish potenti
receiv increas amount interest microdystrophin gene therapi program june day
approach investor present yesterday mani investor question potenti differ
western blot immunohistochemistri assay could mean interpret microdystrophin express data discuss
detail believ two complementari techniqu consid togeth fulli interpret
microdystrophin express patient confid high likelihood initi biopsi data first two
microdystrophin gene therapi patient support ultim success gene therapi program gener upsid
titl link note
updat stomp data show deepen
respons svd arm support
upgrad outperform compel
updat result three arm stomp studi evalu selinexor combin second-lin mm releas
pr morn concurr eha present updat mostli increment vs prior data cutoff abstract
though deepen respons svd arm increment increas orr sdd arm give us add confid
prospect selinexor eventu move earlier line treatment despit recent stock movement believ
addit room share appreci selinexor mm data matur dlbcl data approach
follow impress data oral sma drug curesma weekend upgrad outperform
sector perform believ addl ph i/ii result continu show strong evid target engag potenti rectifi
diseas underli pathophysiolog updat clinic data emerg firefish studi type sma pt show compel
efficaci view increas agent ultim probabl success increas long-term opportun across
sma subtyp see out-yr potenti potenti acceler fda approv acknowledg incomplet data
differ characterist make comparison sma agent spinraza difficult econom agent partner
roch limit stock run high expect nonetheless believ data enough transform
stori drive addl upsid share increas target
better expect data sma
sma data roche/ptct present curesma weekend look better expect highlight potenti risk
long-term revenu opportun spinraza franchis peak annual sale estimate
agenda post tomorrow
 day continu like prospect
macro effect micro-
tomorrow day
made avail websit
found
present day dr jerri mendel present biopsi data first three patient treat
microdystrophin gene therapi program dmd result show robust express microdystrophin patient averag patient
normal express microdystrophin western blot rang relat normal fat/fibrot tissu
show microdystrophin posit fiber result much better expect express level
microdystrophin-posit fiber set compani meaning higher express level
microdystrophin posit fiber believ would mark bar potenti success gene therapi addit averag
copi vector detect per cell suggest success deliveri skelet muscl anoth import metric
distribut express also look tight rang without much variabl also key posit
share today believ base strong data present microdystrophin gene therapi duchenn
muscular dystrophi believ repres overreact buy opportun share
believ compel proof-of-principl microdystrophin gene therapi data present srpt day today substanti
increas likelihood sustain growth compani franchis across muscular dystrophi subtyp long
term despit recent share upsid believ higher probabl success gene therapi likelihood rapid path
market applic approach revenu opportun like limb girdl muscular dystrophi warrant higher
valuat see share appreci emerg onto investor radar de-risk premier neuromuscular
commerci platform increas tgt
emot rais
titl link note
morn report posit data open-label studi jakafi acut steroid-refractori gvhd
huge materi revenu contributor favor data mostli expect follow compani recent bullish
commentari believ help support add growth opportun drug see peak out-year
potenti provid posit news go day today follow string epacadostat baricitinib
morn addit posit gvhd data report earlier announc multipl updat pipelin
press releas prior afternoon day
spotlight uniqu approach
new data combo detail
fgfr ad
begin come togeth
note week fda issu updat draft guidanc mdd clinic trial -- particular note specif pathway acut
chronic dose treatment draw key distinct two approach guidanc appear strongli valid
sage acute-treat paradigm accept valid new approach conduct registr studi treat
depress emphas regulatori buy-in emerg concept continu view sage valuat under-appreci
long-term revenu opportun novel paradigm-shift approach
attend day slide distribut also avail compani websit
note slide contain detail vs
morn pr call follow new datapoint
 slide initi clinic data combo jakafi refractori mf show spleen length reduct week
symptomat benefit initi cohort believ first clinic evid combinatori approach potenti augment
jakafi efficaci believ either via pim brd approach import jakafi life cycl
 slide detail acut gvhd posit data report morn durat respons key look good
month month among day respond increas likelihood approv durabl impt regul
 slide impress waterfal plot fgfr inhibitor ph ii data cholangiocarcinoma among pt transloc
best orr sd respons lower among non-transloc pt though effect serv control
highlight true mechanism-bas activ best orr urothelial/bladd pt look fairli similar report
erdafitinib continu dose pursu compar dose
 slide topic ruxo atop derm among mild moder pt show dose-depend easi score improv iga
respons exce triamcinolon cream activ control highest dose though
attend day compani present sever new datapoint includ promis new result rux gvhd
atop dermat myelofibrosi combo fgfr inhibitor review plan breadth pipelin look build
next chapter beyond jakafi follow epacadostat failur somewhat behind larger compani sever target oncolog
i/o rheumatolog approach pursu potenti enabl learn advanc program also
like necessit high effici pursuit nich potenti lower revenu opportun nonetheless depth scienc
translat work still impress could give edg optim combin molecul long term
like limit credit inci current valuat mid-stag pipelin strong grow jakafi backbon provid high
titl link note
takeaway management meet new
ceo pois guid aldr
opportun sit aldr new ceo bob azelbi along member management team discuss
strateg vision compani on-going clinical/regulatori updat overal impress azelbi oper
experi convers believ serv aldr well regulatori manufactur commerci element take
center stage well deep knowledg compani alreadi given first week continu believ share
underappreci size migrain prophylaxi market meaning potenti blockbust role differenti entrant
like aldr epti could play confid compani stewardship next stage see valu creation
aimovig launch highlight market pk compar studi complet aldr file bla
report tale biotech
report provid updat view biotech sector refresh initi outlook link base
state sector overal see opportun continu sector momentum ye though see interest
valu among larger cap
downgrad sector perform in-
line trade chapter evolv
like limit read-through exondi
chmp re-exam today
downgrad share sector perform outperform adjust price target view
street overreact recent epacadostat baricitinib setback share rebound around
valu believ fairli account substanti jakafi growth opportun out-year patent
cliff probability-adjust pipelin prospect share low thesi mostli play believ
jakafi enabl solid floor compani impress translat work medicin chemistri help set compani
well long-term nearer term would expect share trade line visibl meaning new
today cover kennen mackay see note report chmp reach posit trend vote nerlynx re-
examin reject earlier year examin potenti read-through recal receiv june
refus chmp exondi appeal import differ issu rais nerlynx
exondi limit direct read-through upcom re-examin decis exondi expect mid-octob
howev today decis seen larg unexpect may signal increas willing chmp re-evalu prior
refus optimist way though bullish view predic valu pmo/ppmo microdystrophin
gene therapi eu exondi like expect watch develop close believ eu exondi
sale could reach ultim approv
part outlook publish morn link conduct short survey investor view sector
head/tailwind beats/miss catalyst full result survey includ backpag
listen webcast highlight opportun drug develop stroke agre overlook
could provid meaning long-term revenu opportun believ could contribut out-year revenu
success recent in-licens interest attribut nonetheless believ still earli day place
addit valu stroke portfolio given histor challeng indic await proof-of-concept data
incorpor opportun model continu see valuat fairli balanc ms/sma stabil vs
competit threat risk/opportun pipelin
line thesi discuss extens glpg even report sub-optimal improv cftr
corrector dose top orkambiwhich along partner partial withdraw triple-combo studi believ
cast signific doubt futur glpg/abbv cf franchis
titl link note
boost biosimilar equiti stake
surpris market remain
acquisit watch
afternoon market close celg partner announc posit result ph iii medalist trial luspatercept
noncompetit lung function data corrector pelican studi along partner abbv decis partial walk
away plan studi believ make even challeng glpg assembl test cf asset quickli
effect enough ever compet leader space remov cf valu almost complet model
previou po stock downsid could limit modest expect go promis lead asset filgotinib
low-risk upcom catalyst lower tgt
expect exercis option boost stake biosimilar jv could set liquid event even elect
exercis buy-up option samsung bioepi joint ventur payment increas ownership biosimilar
busi move come surpris given compani commentari letter last month samsung
biolog outlin term time june deadlin place quickli put
posit strength potenti set stage compani turn around sell meaning stake suit
biosimilar asset attract non-cor though exact valu samsung bioepi unclear scenario
roughli assum bioepi make samsung biologicss current market cap biib share could
potenti valu sale would repres attract return compani
exhibit stock cover kennen mackay
titl link note
thought new data point net
posit
script inflect stave concern opdivo yervoy market share eros rcc set per im total weekli
prescript cabometyx week end vs week end rebound follow two
consecut week script declin allay concern immedi competit effect opdivo yervoy rcc
get fda timelin unimpair
tight-lip detail surround abp reject made brief two-sent announc afternoon
fda reject bla abp biosimilar version herceptin roch pend updat management expect
delay major effect model current forecast abp launch follow patent expir
herceptin june current model abp reach peak sale
take orr data
trial improv focu still
kadcyla neratinib combo see improv efficaci tox limit dose saturday updat data
trial neratinib kadcyla trastuzumab-emtansin patient metastat bc present combo show
orr respons efficaci evalu patient cr pr remain patient evalu efficaci
stabl diseas progress diseas gi tox remain concern trial dose neratinib vs
approv dose move forward combin stage trial metastat bc patient
topacio ovarian updat larg
increment focu remain tnbc
today tsro present increment updat topacio studi assess zejula keytruda pembrolizumab
pembro platinum- resistant/refractori ovarian cancer proc
updat arrow data confirm
take remain compel
rraml continu matur
continu look promis pivot
show kyproli dose maintain advantag profil current twice-weekli label r/r mm present
updat data arrow trial assess once-weekli kyproli dexamethason kd vs twice-weekli
dose dexamethason patient r/r mm arrow includ patient receiv two three prior line
therapi top-lin data present in-lin previous announc top-lin data octob showcas
month improv compar twice-weekli regimen addit dose result significantli improv
orr vs improv cr rate vs safeti profil two treatment
arm similar new safeti risk emerg arrow trial
takeaway weekend present updat data ivosidenib inhibitor rraml
inhibitor glioma solid tumor ivosidenib saw larg increment updat os slightli improv
safeti remain larg line report saw limit data initi dose escal trial
sign efficaci toler dose continu focu addit present ivosidenib chemo
combin idhmut aml build limit data seen gain clariti additive/synergist efficaci aml
takeaway weekend present updat enfortumab vedotin ev trial metastat urotheli
carcinoma partner roch present polatuzumab vedotin pola studi follicular lymphoma dlbcl data last seen
ev updat particularli treat prior checkpoint inhibitor cpi remain compel deepen orr os
compar favor vs histor soc experi provid anoth posit read-through on-going potenti pivot
studi popul pola data dlbcl line report though exact addit benefit pola
bendamustin rituximab br vs histor br efficaci remain unclear though note pola meaning driver
valuat potenti upsid model given pola develop roch genentech leverag platform
titl link note
takeaway weekend
keytruda monotherapi data rcc could increas competit market long-term present initi result
single-arm studi assess keytruda monotherapi rcc data overal compel well
receiv physician commun orr overal popul intermediate/poor risk sub-group
patient data remark similar slightli ipinivo
respect orr seen keytruda come ipinivo though keytruda data
remain immatur median dor reach physician commentari post-present quit posit toward initi
find note everi patient need io doublet therapi monotherapi could altern reduc
toxic vs ipinivo keytruda entri rcc would intensifi competit anticip would requir
lengthi random trial continu see role combo io agent nivo best-in-class anti-
vegf tki monotherapi io-refractory/io-progressor
reason buy weak idh
aml combo speed depth durat
takeaway morn present updat find frontlin aml trial idhifa enasidenib ena tibsovo
ivosidenib ivo combin vidaza azacitadin aza idhmut aml patient inelig intens induct therapi
unfit view combo updat highli compel support ena ivo expans potenti set
combo appear benefit durat
take adcetri continu shine
hl sub-group post-hoc analys
takeaway today report updat result forward-ii cohort assess mirvetuximab mirv avastin
platinum-resist ovarian cancer proc respons result larg line press releas though declin
slightli vs abstract potenti creat weak stock specif today poster saw orr
overal popul vs orr abstract subset patient baselin
characterist mirror elig forward-i vs abstract importantli one patient forward-i
elig cohort initi respons yet confirm via second scan potenti boost orr subsequ
followup see preview addit synergist benefit combo vs mirv monotherapi larg come form
longer expect oppos orr improv view benefit combo vs mirv avastin
monotherapi meaning signal could broaden mirv footprint upon potenti approv monotherapi post-
forward-i success see high likelihood occur regardless pivot path forward mirv avastin given potenti
obtain compendia list within nccn guidelin forward-ii dataset continu see mirv keytruda combo
test anoth forward-ii cohort import driver mirv long-term prospect await data updat later
year esmo initi data sgo earlier year see note
takeaway today present sub-group post-hoc analys adcetri studi hodgkin lymphoma hl
focus impact g-csf prophylaxi pet statu outcom differ adcetri avd vs soc avbd
analys show potenti hl adcetri use usa outperform result studi appropri incorpor
g-csf prophylaxi improv safeti well efficaci per modifi importantli benefit seen usa increas
vs seen popul indic adcetri avd could improv patient outcom better real world
usa set given adcetri label recommend g-csf prophylaxi adcetri avd also perform better vs avbd regardless whether
patient petpo petneg see bolster profil post-rathl studi treatment paradigm view data
support high util hl
titl link note
takeaway monday saw competitor read-through rubraca prospect prostat cancer present
lynparza zytiga post-chemo mcrpc well post-hoc analysi data bolster rubraca posit
launch mainten oc competitor lynparza prostat data mix cautious receiv audience/discuss
though see sever differ today lynparza zytiga combo data vs upcom data primarili
program studi post-chemo post-androgen metastat prostat cancer patient higher unmet need lower efficaci
bar view lynparza limit efficaci combo safeti result neg read-through trial
separ present post-hoc analys assess impact variou loh cut-off hrdpo popul
impact tumor burden across differ biomark popul indic rubraca efficaci benefit meaning
experienc regardless stratif view anoth posit rubraca launch mainten
set potenti enabl rubraca meaning compet popul despit launch behind competitor zejula tsro
lynparza azn
confound tsro consid
 corpor updat takeaway follow market close yesterday tsro present updat data tripl neg breast
cancer tnbc cohort keytruda zejula combin arm topacio trial held investor event quadra
data addit present earlier yesterday
compel competit profil
promis data cemiplimab metastat cscc present publish nejm monday
present primari analysi metastat cutan squamou cell carcinoma cscc cohort trial cemiplimab
patient treat cemiplimab achiev orr durabl dcr median mo observ respons
median dor os yet reach time data cut-off cemiplimab well toler common teae
diarrhea fatigu nausea common grade higher teae pneumon anemia diarrhea fatigu
constip result stack favor compar data carskin trial pembrolizumab metastat cscc
show orr dcr report median mo os yet reach common teae
fatigu rash pain common grade higher teae relat impair liver function also
present addit result expans cohort trial cemiplimab patient local advanc metastat cscc
result expans cohort line result present trial patient treat cemiplimab
achiev orr durabl dcr mean mo respons common teae studi fatigu
common grade hypercalcemia one uti set result simultan publish nejm
present updat result pace-md studi monday present updat result
pace-md trial luspatercept patient md efficaci respons data increment improv vs decemb updat
see note slight increas iwg hi-e respons transfus independ driven sever esa-na
patent though durat transfus independ slightli declin iwg hi-e rbc-transfus independ rbc-ti
present includ exhibit page iwg hi-e rbc-ti rate increas slightli among evalu patient
respect patient baselin epo level iu/l iwg hi-e rbc-ti rate rose respect vs
prior updat new data report patient baselin epo level iu/l mean durat treatment
rbc-ti respond mo slightli mo continu evolv overal patient
achiev clinic meaning improv iwg hi-e patient achiev
rbc-ti least week respons rate slightli higher esa-na patient iwg hi-e
rbc-ti patient overal studi popul
fulphila approv fda pt
expect fulphila approv pend biosimilar approv creat signific headwind neulasta sale
titl link note
note road post-asco ndr
detail thought ever-chang rcc
script analysi declin short
week outperform peer track
beat
dupi script declin short week
flatten trend though well
model updat push eu
commerci sale account earli
cash-effici bd core compet
takeaway yesterday conduct day meet exelixi ceo dr michael morrissey cfo christoph senner evp
public affair investor relat susan hubbard investor discuss focus clinic updat cabozantinib cabo
competit agent immuno-oncolog io landscap potenti differenti io
agent commerci dynam within rcc market post-april opdivo yervoy rcc approv cabo fda snda accept
recent hire busi develop plan valid third-parti script data ims/symphoni remain confid
traction rcc potenti beat st estim potenti expans addit indic
combin immunotherapi
script declin wk/wk short holiday week trend outperform tki support continu growth per
morn im data cabozantinib total script fell wk/wk vs last week short week end june
metyx exclus cometriq though back memori day holiday suggest growth put context
continu growth support comparison class-peer votrient sutent saw significantli higher wk/wk declin
respect support rel out-performance despit short/down week across im channel
put product-specif growth perspect vs class market dynam see exhibit overal wk/wk script trend
quarter remain posit though slow averag growth vs compar period
first launch rcc opdivo yervoy competit absent
takeaway weekli dupix dupi wk/wk week end inclus memori day holiday
wk/wk week prior overal wk/wk flatten averag compar averag growth
compar period indic growth may slow though note total script compar
period grown significantli vs given strong run-rat achiev end flatten
concern dupi run-rat remain promis ad howev see complex translat script analysi quarterli revenu
aimovig script significantli wk/wk second week launch week end consider
previou week aimovig first week launch trajectori continu indic pent demand cgrp
therapi line individu physician commentari highlight wait list contain hundr interest patient
provid bolu new start see nyc doc day takeaway
updat model push eu rubraca sale account eu earli access program lower
price target
continu bd effort potenti ad neurodegen disord complement focu morn
announc partnership agreement complement pharma dutch privat compani preclin lead asset
monoclon antibodi target complement compon preclin data support therapeut efficaci
sever neurodegen disord specif indic disclos commit million mileston
payment complement pharma see develop partnership also provid option
acquir complement time like partnership allow manag focu core scientif compet
complement biolog cash effici manner like bd focu larg under-the-radar/under-appreci asset
await detail develop plan remain upsid valuat await clariti target
indic preclin data
titl link note
eye transit
commerci stage new ceo hire
oral hear confirm neratinib
remain conserv eu
scenario analysi upcom
achondroplasia initi younger
patient follow encourag adcom
script recov continu track
dupi script rebound new high
follow holiday week
takeaway today market close announc appoint dr jayson dalla compani new ceo recal
former ceo dr stephen dilli announc last year intent retir end remain special advis
prepar regulatori file dr dalla bring substanti commerci experi new role serv
chief commerci offic ultragenyx well hold senior commerci role roch genentech novarti proctor
 gambl previous given near-term transit becom commercial-stag compani see dr dalla hire
appropri anticip commerci expertis could bolster commerci success
takeaway yesterday market close announc eu chmp conduct oral hear june discuss
re-examin neratinib extend adjuv bc
detail sever outcom edelweiss endometriosi data upsid scenario rang
vs downsid scenario pt buyer data anticip high likelihood
achiev best-cas scenario competit high-dos requir hormon add-back like competit competit
lower dose requir add back
first patient dose studi vosoritid younger infant/toddl achondroplasia patient morn announc
treatment first patient studi vosoritid infants/toddl line guidanc trial start
press releas also detail trial design slightli larger trial vs preliminari design guidanc rnd day
endpoint in-lin guidanc safety/toler growth z-score secondari includ proportion function
qualiti life sleep apnea foramen magnum dimens well advent major ill surgeri importantli
studi enrol youngest patient treat vosoritid to-dat could confirm extrapol hypothes rnd
day growth rate height increas inch achiev vosoritid treatment studi
could enabl achondroplasia patient achiev termin height low rang normal sustain cours
patient entir growth phase see note model vosoritid launch ahead st estim though
conserv longer term estim sale vs st
takeaway morn updat iqvia number metyx indic script increas wk/wk vs
week end vs week end short week inclus memori day holiday uptick consist
tki peer larg saw increas script volum vs shorten previou holiday week see exhibit
growth place trajectori averag wk/wk growth date remain track beat est im
tracker impli assum continu wk/wk growth assum flat wk/wk growth remain week
sale vs st vs wk/wk growth date lower vs seen compar
period total script period vs compar
takeaway weekli dupix dupi trx wk/wk reach new peak weekli script
wk/wk week prior overal wk/wk trend upward per week compar averag growth
compar period week script growth temper concern growth may slow dupi script rebound follow
holiday week larg growth wk/wk somewhat expect given full week data compar week preced
one inclus memori day holiday howev new high weekli script give ad confid sustain upward
trend dupi script growth
titl link note
updat continu suggest durabl
takeaway press releas updat result luspatercept beta-th studi ahead full present tomorrow eha
first glanc appear respond rate non-transfus depend ntd transfusion-depend td
come meaning vs dataset previou iter last year eha though artifact differ
assess respond rate vs luspatercept lack durabl specif proport ntd respond achiev
increas hemoglobin hb come vs previous similarli proport td
respond defin achiev reduct transfus also came vs previous
howev importantli caveat today updat assess respond rate fix interv week
similar assess done believ studi oppos best interv report
prior data iter fix data present ntd popul though previous report
td popul eha respond rate line today updat
aimovig script growth posit though remind unlik impact earn aimovig script continu rapid launch
growth total script track week end june previou report week
end june previou week view number increment posit underli
pent-up demand cgrp therapi caution unlik indic revenu two primari reason
weekend read ahead monday
takeaway today market close obsv announc releas edelweiss data pre-market monday
morn conjunct et investor call us confer id
differenti add-back dose
durat treatment data present eha luspatercept beta-th see increas non-transfus depend ntd
patient present updat result luspatercept beta-th trial weekend eha notabl impress
median durat treatment data present luspatercept reach mo ntd patient achiev
increas hemoglobin hb vs mo report previous eha
takeaway obsv top-lin edelweiss result endometriosi result blend best case next-best-
case scenario outlin edelweiss preview see high-dos option provid full suppress
show in-lin potenti superior efficaci high-dos elagolix lower-dos option
provid moder suppress therefor requir estrogen add-back therapi in-lin competit efficaci
compel endometriosi
view linzagolix endometriosi result favor demonstr in-lin high-dos potenti best-in-class
low-dos option provid linzagolix compel valu proposit compet effect despit behind develop
increas po linzagolix endometriosi opportun await obsv catalyst includ edelweiss
efficaci bmd data nolasiban live birth data initi pre-term labor data
review could add upsid estim
takeaway morn announc submiss biolog licens applic bla fda
treatment pnh includ surpris use prioriti review voucher prv gain expedit review use prv gain
review period vs standard month like lead earli us launch ahead st expect
model us sale vs global st estim pnh foa consensu estim split
quarter us estim base mid-year launch see earli launch like lead upsid revis
growth channel captur remain
takeaway market close today updat monthli symphoni data releas indic may vs april
titl link note
skeptic acquisit
takeaway morn tsro share follow unsubstanti media report bloomberg suggest acquisit interest
roch skeptic roch acquisit given see lack compel strateg rational detail
point
continu track toward beat
takeaway morn updat iqvia number metyx indic script declin wk/wk vs
week end vs week end
dupi script dip remain track
takeaway weekli dupix dupi fell slightli wk/wk continu trend quarterli growth dupix fell
week end june slightli all-tim high report last week
aimovig launch continu show high
demand rapid growth
aimovig trx growth rate slow week end june continu impress launch trend four week
morn iqvia number week end june report anoth strong week growth aimovig wk/wk
vs week end june slow growth rate week end june
june june respect overli concern given earli stage launch continu hear physician
start treatment initi bolu preval patient eagerli await launch aimovig
aimovig script over-st iqvia
takeaway iqvia inform us aimovig trx captur mail channel consist total volum
overst sinc drug launch week end week end first three week launch iqvia re-
state aimovig trx first three week amount declin total volum declin mail channel
week week week respect
posit outcom narrow label
parpi releas posit
expect though void detail
competit impact
take morn commun chmp reach posit opinion today re-examin
neratinib breast cancer extend adjuv set see surpris given expect neg
outcom follow initi neg vote major investor also expect second chmp neg trend vote
buysid survey publish morn see exhibit link note
takeaway morn astrazeneca azn merck announc lynparza studi brcamut mainten
ovarian cancer met primari endpoint pr scant detail regard benefit hr though cite
result statist signific clinic meaning improv vs placebo note result wide
expect posit may headlin weak tsro share view trial outcom
remov key overhang tsro
see limit impact valuat arri braftovi mektovi approv braf-mut melanoma array arri
biopharma announc afternoon receiv fda approv braftovi encorafenib mektovi binimetinib
combin patient advanc braf-mut melanoma third brafi meki combo obtain fda approv
set join exel/rog cotel zelboraf novarti mekinist trametinib tafinlar dabrafenib note
market alreadi seen pressur competit meki brafi well immuno-oncolog seem show best-in-
class efficaci date recent data label see limit impact given cotel alreadi limit revenu
contribut rog/gen royalti stream recal cotel subject world-wide collabor agreement rog/gen
deliv total product revenu total cotel royalti melanoma
account less current target price
merger equal add commerci
takeaway morn akebia keryx biopharmaceut kerx announc two compani agre
all-stock merger expect close come surpris us compani focu nephrology/ckd
products/develop transact strateg synergist valu could year away given vadadustat develop
titl link note
varubi divestitur come expect
takeaway today market close tsro announc enter asset purchas agreement tersera
therapeut divest iv oral varubi north american right continu commerci varubi eu
retain row right sub-licens tersera announc come surpris us given tsro prior
guidanc earn call discontinu market iv varubi due case anaphylact reaction see
takeaway potenti pursu sale asset
takeaway today present addit aimovig data american headach societi ah meet includ efficaci
data chronic migrain safeti data episod migrain ole studi
luspatercept succe medalist
believ next near term focu
luspatercept posit medalist trial larg anticip though confirm posit outcom increas estim
probabl success previous increas pt believ trial schedul read
immin addit see success larg bake in/appreci
exhibit stock cover georg hill stephen hagan
titl link note
hc distribut mind look
deal spread week rule
look ahead t/twx decis investor anxieti spike ahead t/twx decis recent inbox incom call volum
seem investor anxieti around vertic integration-them stock esrx spike ahead expect t-time warner
case rule expect tuesday june believ rule like short term impact share stock
tie vertic integr deal though believ actual t/twx case may littl relev whether doj
choos challeng cvs/aetna cigna/esi transact due politic natur media transact esrx share could
provid near term out-performance option market impli move share t/twx decis thu strategi
would increas exposur esrx share weak relat t/twx rule
today announc manag team combin -aet compani follow close transact view
chang larg expect possibl except aetna cfo select cfo combin compani
busi unit leader aetna busi execut current lead busi
ad respons transform initi integr effort
athn begin end athena
explor strateg option ceo
athenahealth announc today board start process explor strateg altern consid sale merger
transact well continu independ compani athena also announc ceo jonathan bush step
role ceo board member view strateg review ceo chang expect given pressur
sharehold recent headlin regard mr bush
posit slightli second half may
total short interest increas two-week period end healthcar technolog distribut hct coverag
univers short interest increas two-week period end term total share increas weight
averag basi weight market cap share short percent float substanti larg cap healthcar
averag investor remain cautiou overal outlook hct univers technolog vendor pharma
distributor saw moder decreas total short interest wherea dental anim health medic distributor pbm drug
retail pharma servic compani saw moderate-larg increas
blur line mdso buy post-approv
medidata announc acquisit shyft analyt shyft increas medidata exposur post-approv
data analyt market posit compani capit grow demand real world evid solut
top concern hear investor esrx share would trade stand-alone compani given current macro sentiment
drug suppli chain believ share could trade trough ep estim short term impli
downsid deal break
navig co-pilot sell
stake navihealth
posit sell major navihealth busi privat equiti partner believ navihealth
manag team pe partner deliv focu asset potenti drive faster growth also view
posit allow medic segment manag focu attent challeng busi within
volum slightli may
retail volum slightli may iqvia npa retail-level prescript data may show adjust volum
y/i basi script dispens retail mail volum data repres
modest neg suppli chain may mark third consecut month declin volum y/i
titl link note
partnership model continu
walgreen today announc partnership open two senior-focus primari care clinic kansa citi walgreen
store coordin in-stor health navig support view partnership consist expect
walgreen continu pursu partnership vertic integr strategi push health insur primari care
clinic run subsidiari partner primari addit four partner primari center alreadi
kansa citi area walgreen also work togeth provid in-stor health navig servic mainli focus
humana medicar member view partnership indic walgreen abl use partnership model
offer competit servic integr aetna note indic size clinic squar feet repres
meaning portion front store would expect lost front store sale off-set higher prescript
market share within kansa citi humana medicar membership
look increment minuteclin
recent meet discuss open minuteclin drive util captur margin opportun low-cost
site care note examin margin opportun estim open minuteclin would net
centuri end replac
ge
hour wsj report walgreen would replac ge jone industri averag view modest posit
like drive short-term demand advanc inclus larg etf dia asset optic
believ inclus drive retail investor demand well suggest larg stabl stock note
healthcar represent increas time healthcar grown percent us walgreen join
healthcar repres
ca dept insur hear cvs/aet merger afternoon american medic associ spoke
deal nation largest physician lobbi group said would releas memo detail analysi later month
note anticip merger would result increas drug spend out-of-pocket cost patient well higher
insur premium reduct qualiti insur view speak protectionist bia ama
implic merger believ key compon merger cvss abil steer beneficiari higher-
cost practic emerg depart lower-cost retail clinic telemedicin urgent care clinic thu compromis
pocketbook ama believ regul see self-interest protest ama continu expect
deal close
amazon berkshir hathaway jp morgan announc appoint dr atul gawand ceo partnership
us healthcar dr gawand surgeon brigham women hospit professor depart health polici
manag harvard chan school public health professor surgeri harvard medic school well
author dr gawand also execut director ariadn lab joint center health system innov chairman lifebox
earli sign stabil
patterson guid ep bracket consensu could indic oper trend stabil concern dental
sale trend like persist quarter continu look stabil across busi consid becom
posit busi valuat
manag
recent road meet investor came away meet believ best posit
wholesal issu outsid control limit opportun posit ep revis multipl expans keep us
neutral share
titl link note
strong gate
hear front hous va committe regard implement ehr system today act secretari
va peter orourk note va issu first three task order begin implement ehr
three washington state hospit octob plan ehr run march develop
repres modest posit believ could start reflect revenu contribut
task order in-hand
walgreen report result thursday bmo ep estim street believ buy-sid
expect modest beat fear recent macro soft rx trend could weigh modestli result
cro virtual realiti note
kpi look soft
enter script distribut
rite aid report result exceed consensu expect revenu ebitda pharmaci gross margin
improv continu main driver though kpi continu erod maintain sector perform rate caution
around posit pharmaci market
buzzword bingo dia recent attend annual drug industri associ confer boston lead trade show
late stage clinic research space focu confer last year increasingli shift toward
technolog year confer much look capabl futur seem everi present hit
year key buzzword data world evid artifici intellig trial virtual trial virtual topic
seem gener interest seem best idea acceler trial enrol drive particip
retent time lower trial execut cost said virtual process infanc
low custom adopt almost regulatori track record
report result ahead consensu deliv ep vs street howev
beat line driven lower tax rate share count oper result came soft notabl same-stor rx flat
front-end same-stor comp compani focus profit announc dividend increas
whop share repurchas program expect soft kpi carri day share perform like soft despit
beat repo program also caus investor question compani deal option go forward
amazon announc acquisit pillpack on-line pharmaci serv peopl take multipl daili prescript
news sourc report pillpack gener revenu serv patient impli
patient take three rx per month -or dispens rx per year share pillpack deliv medic
pre-sort dose packag coordin refil renew emphas shipment deliv time cnbc report
april discuss acquir pillpack drug suppli chain share trade sharpli
news would expect suspect amazon offici entri space place cap drug suppli chain multipl
regardless whether amazon abl scale pillpack busi
exhibit us med-tech spec pharma coverag valuat tabl
note appli growth rate base number arriv data price market close june
pricemcapevev/salesforecast growthev ebitdaforecast growthpeforecast growthloc currencyloc compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate bax-ussector dickinson companybdx-ussector corporationbsx-ustop wmgi-usoutperform spec biomet itgr-ussector lifesci iart-ussector group hold trxc-usoutperform spec aray-ussector surgic isrg-ussector medic systemsvar-ussector ops-caoutperform spec riskcad tos-casector perform spec riskcad med-tech pharmaacelrx pharmaceut acrx-usoutperform spec therapeuticsagrx-usoutperform spec akrx-ussector depo-ussector perform spec pharmaceut endp-ussector biosciencesevfm-usoutperform spec therapeuticsflxn-usoutperform spec therapeuticsinsy-usoutperform spec pharmaceut spec therapeuticsgud-caoutperformcad spec prgo-ussector performila spec pharma exhibit us biotech coverag valuat tabl
factset capit market estim price market close june
pricemcapevev/salesforecast growthforecast growthforecast growthloc currencyloc compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate vrx-ussector perform dvax-usoutperform spec risk sino-usoutperform spec risk ptct-ussector perform nologypbyi-ussector perform spec risk srpt-usoutperform onc-caoutperform spec riskcad nvln-ussector perform spec risk life scienc pli-caoutperform spec riskcad saabvx-froutperform spec risk saup-caoutperform spec riskcad once-usoutperform spec risk abeo-usoutperform spec risk biopharmaceuticalsaldr-usoutperform sbcrx-usoutperform spec risk na na na biib-ussector perform celg-ustop pick senta-ussector perform nvglpg-nlsector perform sciencesgild-usoutperform design imdz-usoutperform spec risk corporationincy-ussector perform sicpt-usoutperform therapiesitci-usoutperform spec risk kpti-usoutperform spec risk mrus-ussector perform spec risk pti-ussector perform spec risk sage-usoutperform svrtx-usoutperform pharmaxlrn-ussector perform sagio-usoutperform aimt-usoutperform spec risk akba-ussector perform salxn-usoutperform amgn-ussector perform perform spec risk atnx-usoutperform bmrn-ussector perform oncolog clvs-usoutperform prime fprx-usoutperform spec risk saobsv-usoutperform spec risk prta-ussector perform spec risk srarx-usoutperform spec risk sregn-ussector perform geneticssgen-usoutperform perform ebitdap exhibit us healthcar servic healthcar technology/distribut coverag valuat tabl
note dr aet evhc lhc qhc qsii appli growth rate base number arriv data price market close june
